Our Management

Ken Giacin joined StemCyte in 2003,bringing world-class leadership to guide the company’s growth through new investments and technological affiliations.

Ken had an outstanding and diverse career with Johnson & Johnson that spanned almost 26 years. His last assignment was Senior Vice President of Independence Technology, L.L.C., a Johnson & Johnson Company, which he started, that is dedicated to providing innovative products to people with disabilities and was responsible for all aspects of managing new business opportunities worldwide, a key element in building a global franchise within Johnson & Johnson.

Ken served Johnson & Johnson in a series of assignments from 1974 to 1991. Beginning in Engineering and Operations with the Domestic Operating Company, he progressed through responsibilities in Operations, Marketing and Business Development and served on the Management Boards of the Baby Products Company as well as Consumer Products, Inc. as Vice President, Business Development.

From 1991 until his return to J&J in 1995, Ken was a Corporate Officer and Vice President, Worldwide Business Development for the Church & Dwight Company reporting to the Chairman. He was responsible for developing brand value and business for the Arm & Hammer Brand on a worldwide basis. In 1994, he added research and development responsibilities as Vice President, Business Development and Technology.

Prior to joining Johnson & Johnson, Ken served with the United States Navy as a carrier pilot and remained actively involved in aviation and non aviation command assignments with the Naval Reserve until his retirement in 1999 with the rank of Captain. He holds a Bachelors of Science, Masters of Science and an MBA, all from Rutgers University.

Mr. Ken has also served on a number of Boards and Advisory Panels including:

  • Board member of Cerebral Palsy of New Jersey.
  • Advisory Board of the Human Engineering Research Laboratory of the University of Pittsburgh.
  • Industrial Advisory Committee to Rutgers University.
  • Advisory Board of the National Institute for Child Health and Development (NIH)s.
  • Advisory Board of the Pan Pacific Symposium for Stem Cell Research.
  • Was named to the Board and Executive Committee of the newly formed Cord Blood Association.
  • Was recently named to the Board of Directors of Sealantis, a wound closure start-up company based in Israel.

Inspired and guided by her father, Dr. Prathap C. Reddy, the pioneer of corporatized healthcare in India, Preetha had formally joined Apollo Hospitals as Joint Managing Director in 1989 and five years later, she became the Managing Director of the Group. A forerunner of integrated healthcare in Asia and globally, Apollo Hospitals’ has been in a position of strength at every touchpoint of the healthcare delivery chain.

The group’s presence includes quaternary and tertiary care hospitals in urban and semi-urban India, primary care & diagnostic family clinics, pharmacies, health education and research endeavours, global clinical trials, wellness, healthcare consulting, business process operations and healthcare technology services. Since inception in 1983, Apollo Hospitals has been honoured with the trust of over 26 million patients.

The group’s presence includes quaternary and tertiary care hospitals in urban and semi-urban India, primary care & diagnostic family clinics, pharmacies, health education and research endeavours, global clinical trials, wellness, healthcare consulting, business process operations and healthcare technology services. Since inception in 1983, Apollo Hospitals has been honoured with the trust of over 26 million patients.

With an aim to harness the growing mobile penetration in India, Preetha had initiated partnerships with telecom providers and Apollo Hospitals pioneered m-health solutions in India. These path breaking mobile healthcare partnerships are set to transform the delivery of healthcare across India and will accelerate Apollo Hospitals’ vision of touching a billion lives.

She works with industry bodies and the Government of India to advance policy decisions on important healthcare issues. In 2009, the Hon’ble Prime Minister of India, Dr. Manmohan Singh, invited her to join the Indo-U.S. and Indo-Malaysia CEOs Forum, think-tanks created to strengthen bilateral cooperation and trade.

Dr Preetha Reddy was ranked in the International list of “50 Most Powerful Women in Business”, by Fortune in 2010 and 2011, and also in ‘The Most Powerful Women in Business’ List compiled by Fortune India – 2011. She has been a regular in the Business Today’s list of powerful business women since 2006.

Preetha was a Founding Member of the National Quality Council, an organization which had provided the guidelines on minimum quality standards to Indian Hospitals. In addition to being an Executive Member on the Board of Apollo Hospitals Enterprise, she is a Member of the Wipro Business Leadership Council and a Governing Board Member of XLRI Jamshedpur. Preetha Reddy was a recipient of a Life Time Achievement Award for distinguished service in the field of Social Science from the Loyola Forum for Historical Research.

Dr. Preetha has been at the forefront of working for the less fortunate and an inspiring example is SACHi (Save a Child’s Heart Initiative) – an endeavour to treat underprivileged children with congenital heart diseases. Under the auspices of SACHi, over 5000 cardiac surgeries have been performed and over 50,000 underprivileged children have been screened for cardiac ailments. She has also played a vital catalyst in facilitating prompt medical emergency response to numerous calamities. Dr Preetha Reddy is the pioneer and chief architect of the TLC mantra, a pillar of the Apollo way.

Dr. Preetha Reddy holds a B.Sc from Stella Maris College Chennai, and a Masters in Public Administration from Madras University. She received formal training in fine-arts at Kalakshetra, Chennai and this helped her further imbibe traditional Indian art and culture. Preetha Reddy was conferred the Degree of Doctor of Science (Honoris Causa) by the Tamilnadu Dr. MGR Medical University, Chennai in recognition of her outstanding work in the field of healthcare. Dr. Preetha is married and has two sons.

Dr. Rajiv I. Modi, Managing Director, Cadila Pharmaceuticals is a Ph.D. in Biological Science from the University of Michigan, Ann Arbor, USA. He obtained his M.Sc. in Biochemical Engineering from University College, London and B.Tech. in Chemical Engineering from Indian Institute of Technology (IIT), Bombay, India.

Dr. Modi joined the Board of Directors of Cadila Laboratories in 1991; restructured in 1995 and re-christened as Cadila Pharmaceuticals Limited (CPL). At present, Dr. Modi is Managing Director of Cadila Pharmaceuticals and Casil Industries Limited, and Director of Cadila Pharmaceuticals Group Companies – Karnavati Engineering Limited (KEL), IRM Limited and CPL Infrastructure Pvt. Ltd.

Upon assuming leadership of Cadila Pharmaceuticals, Dr.Rajiv I. Modi charted a multi-pronged approach for Cadila Pharmaceuticals’ corporate growth. Envisioning a global presence for the group, Dr.Modi played a pivotal role in establishing marketing set-up and subsidiaries of Cadila Pharmaceuticals across the shores. Today Cadila Pharmaceuticals has a strong presence in the global arena with operations in the USA, Japan, CIS, and Africa; with its first overseas formulations manufacturing unit at Addis Ababa, Ethiopia.

Cadila Pharmaceuticals has affiliations with leading companies and manufacturers across the globe, and has imbibed world-class technologies in its operations. A perfectionist and visionary, Dr. Modi incorporates excellence and quality into the company’s operations and ethos.

At Cadila Pharmaceuticals, there is immense focus on research. Being a Biotechnologist himself, Dr.Modi has played a major role in developing the Biotechnology Division at Cadila Pharmaceuticals into a strong Research and Development unit, focusing on new developments and breakthrough innovations. Collaborative research in Biotechnology is being carried out at various National and International Research Laboratories like IMTECH, Chandigarh; IISc, Bangalore; NII and CBT, New Delhi; ICGEB, New Delhi & Trieste, Italy.

In keeping with Cadila Pharmaceuticals’ vision to be a global company, Dr. Modi has brought a cutting edge to all the operations within the Cadila Pharmaceuticals group – be it Marketing, Human Resources, Technological upgradations, infrastructure building or sharpening the core competencies of the group. Under his leadership, the group is setting up a Pharmaceutical Sector specific Special Economic Zone – PhaEZ Park – near Ahmedabad in Gujarat spread over 200 hectares. He has also led Cadila Pharmaceuticals to acquire a significant stake in Novavax Inc. USA.

He also launched CPL Biologicals, a joint venture between Cadila Pharmaceuticals and Novavax Inc. USA, hence, bringing the most advanced technology in vaccine manufacturing to India. The company, under his leadership, has also entered into a strategic alliance with the Swedish Bactiguard which provides world-leading solutions preventing hospital-acquired infections.

Dr. Modi has also been actively participating in the exemplary development of the state of Gujarat. As a part of Vibrant Gujarat celebrations, he led the industrial delegation from the state to Japan in 2009 to strengthen the business ties between the two countries. Eventually, Japan became the partner country in Vibrant Gujarat. Recently, Dr. Modi also got elected as the Vice Chairman of the apex industry body CII, Gujarat State Council for the year 2012-13.

Dr. Modi is a member of The New York Academy of Sciences, USA; Genetic Society of America; American Society for Microbiology; Industrial Biotechnology Task Force, New Delhi; Technical Panel on Biotechnology, Gujarat; Indian Chemical Engineer, India and TIFAC. Dr. Modi has also been elected as Fellow of Indian National Academy of Engineering, New Delhi. This elite academy has prominent industry leaders, academicians and scientists amongst its Fellows.

Dr. Wise Young is Distinguished Professor of Cell Biology & Neuroscience, Richard H. Shindell Chair in Neuroscience and Founding Director, W.M. Keck Center for Collaborative Neuroscience at Rutgers, The State University of New Jersey, is one of the world’s most outstanding neuroscientists and a foremost leader in spinal cord injury research.

With a B.A. from Reed College, a Ph.D. from University of Iowa, an M.D. from Stanford University and a Surgery Internship at New York University (NYU) and Bellevue Medical Center, he became Director of Neurosurgery Research at NYU. He was a part of the team which discovered and established high-dose methypredisolone (MP) as the first effective therapy for spinal cord injuries.

He has appeared as a guest on “20/20″, “48 Hours”, “Today”, “Eye to Eye”, Fox News and CNN. His work has been featured in a Life magazine special edition, in USA Today, and in numerous news, talk and print presentations worldwide.

His honors to name a few include: NIH Jacob Javits Neuroscience Award (1985-1992), Wakeman Award (1991), Tall Texan of the Year Award (1997), “Cure” Award (1998), Trustees Award for Excellence in Research (2001), 2002 Asian American Achievement Award, Douglass Medal for work with the advancement of young women in the sciences (2003), and Elizabeth M. Boggs Award for service to the disability community (2004).the Recent award includes Everfront Award for Stem Cells and Cancer Research (Taipei, Taiwan) (2013); BioNJ Patient Advocacy Award (New Brunswick, NJ) (2014).

In August 2001, TIME Magazine named Dr. Young as ‘America’s Best’ in the field of spinal cord injury research.• In 2005 he was the first researcher elected to the Spinal Cord Injury Hall of Fame. In 2006, Dr. Young received The Hope Award – A Salute to Research Innovation, the New Jersey Educator of the Year Award, and the Caring Heart Award.

When the Richard H. Shindell Chair in Neuroscience was established at Rutgers University in 2006, Dr. Young was named as the first person to hold that chair.•In 2007 the Motolinsky Foundation named Wise Young as the recipient of their Distinguished Citizen Award. Dr. Young also serves as Chairman of the Advanced Therapeutics and Clinical Studies Committee.

Current Advisory Positions and Board Memberships

  • 2007-now: Board of Directors, Hong Kong Spinal Cord Injury Fund (Hong Kong).
  • 2011-now: Global Medical Director, Stemcyte, International Inc;.
  • 2013-now: Board of Directors, Stemcyte India.
  • 2011-now: Scientific Advisor, Acorda Therapeutics, Hawthorne, NY.

StemCyte India Therapeutics Pvt. Ltd.

He is Graduate in Science from Bangalore University with post-graduation in general management from Indian Institute of Management-Bangalore .

He has successfully completed 24 years in Indian Pharma Industry in various functions with deep knowledge in the areas of Critical Care, Women’s Health, Oncology, Vaccines, Bio-Surgery, Nutrition and Bone Health. Worked for some of the best companies-Wockhardt, AstraZeneca, MSD, Sanofi Genzyme, Eli-Lilly and Mylan. Specialized in handling the P&L, Strategic Planning, Tactical Approaches, Business Development, Product Launches and Branding. Successful track record in Product Launches, Innovation, Key Account Management, Sales Operations, start up business, hiring, talent management and people development. Highly adaptable to VUCA environment & have successfully led the teams in addressing disruptive problems & managing potential risks.

Outstanding success in building and maintaining relations with Key Opinion Leaders, Corporate Clients & NGOs; Established large volumes, drove high profit accounts with excellent levels of key account retention and loyalty to the core business. Accomplished qualifications with continuous update of the commercial knowledge. Proven skills in breaking new avenues, problem solving, data-mining & proactive opportunity assessment by keeping abreast the market trends/ competitor moves to achieve market-share. Maintained high standards of business ethics, compliance & business hygiene in reaching the financial goals. Exposure to pan India geographies in various therapy segments.